Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
US-2016304535-A1 · Oct 20, 2016 · US
US10035809B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10035809-B2 |
| Application number | US-201715599151-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 18, 2017 |
| Priority date | Dec 21, 2012 |
| Publication date | Jul 31, 2018 |
| Grant date | Jul 31, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R 1 , X, W, Y 1 , Y 2 , Z 1 , and Z 4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Opening claim text (preview).
What is claimed is: 1. A compound having Formula (I): or a stereoisomer or pharmaceutically acceptable salt thereof, wherein: X is —NZ 3 —; W is —CHZ 2 —; Z 2 is hydrogen; Z 1 and Z 3 , taken together, form -L-, wherein L is —C(R a ) 2 —; Z 4 is —CH 2 CH 2 —; Y 1 and Y 2 are each independently hydrogen, C 1-3 alkyl or C 1-3 haloalkyl; R 1 is phenyl substituted with one, two or three halogens; and each R a is, independently, hydrogen, halogen, hydroxy or C 1-4 alkyl. 2. The compound of claim 1 , wherein the compound is selected from the group consisting of: 3. A pharmaceutical composition comprising a compound of claim 1 , or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
for HIV · CPC title
Antivirals · CPC title
Bridged systems · CPC title
spiro-condensed or forming part of bridged ring systems · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.